Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VRTX 
Vertex Pharmaceuticals Inc (VRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: VRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
34 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $481.76
1 Year Target Price $481.76
| 14 | Strong Buy |
| 4 | Buy |
| 14 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.1% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 104.55B USD | Price to earnings Ratio 28.98 | 1Y Target Price 481.76 |
Price to earnings Ratio 28.98 | 1Y Target Price 481.76 | ||
Volume (30-day avg) 34 | Beta 0.43 | 52 Weeks Range 362.50 - 519.88 | Updated Date 10/13/2025 |
52 Weeks Range 362.50 - 519.88 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 14.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 31.86% | Operating Margin (TTM) 38.93% |
Management Effectiveness
Return on Assets (TTM) 12.54% | Return on Equity (TTM) 22.77% |
Valuation
Trailing PE 28.98 | Forward PE 20.92 | Enterprise Value 99969917661 | Price to Sales(TTM) 9.16 |
Enterprise Value 99969917661 | Price to Sales(TTM) 9.16 | ||
Enterprise Value to Revenue 8.75 | Enterprise Value to EBITDA 21.78 | Shares Outstanding 256390651 | Shares Floating 255577893 |
Shares Outstanding 256390651 | Shares Floating 255577893 | ||
Percent Insiders 0.14 | Percent Institutions 98.22 |
Upturn AI SWOT
Vertex Pharmaceuticals Inc
Company Overview
History and Background
Vertex Pharmaceuticals Inc. was founded in 1989. Initially focused on HIV protease inhibitors, it pivoted to cystic fibrosis (CF) therapies. Its first CF drug, Kalydeco, was approved in 2012, marking a significant milestone. Vertex has since become a leader in CF treatment.
Core Business Areas
- Cystic Fibrosis (CF): Develops and commercializes therapies for treating cystic fibrosis, a genetic disease affecting the lungs and other organs.
- Other Therapies: Researching and developing treatments for other diseases, including pain, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney disease and sickle cell disease (SCD).
Leadership and Structure
Reshma Kewalramani, M.D., Ph.D. is the current Chief Executive Officer and Chairman of the Board. The company has a functional organizational structure with distinct research, development, and commercial teams.
Top Products and Market Share
Key Offerings
- Trikafta/Kaftrio: A triple combination therapy for CF patients with at least one F508del mutation. It holds a significant share of the CF market. Competitors are primarily focused on gene therapies or alternative approaches to CF treatment, such as antisense oligonucleotides. The drug accounted for the overwhelming majority of total product revenue.
- Kalydeco: A CFTR potentiator for patients with specific gating mutations. It was Vertex's first approved CF drug. Competitors are same as Trikafta/Kaftrio. Revenue is declining as patients switch to Trikafta/Kaftrio.
- Orkambi: A combination of lumacaftor and ivacaftor for CF patients with two copies of the F508del mutation. Revenue is declining as patients switch to Trikafta/Kaftrio.
- Symdeko/Symkevi: A combination of tezacaftor and ivacaftor for CF patients. Revenue is declining as patients switch to Trikafta/Kaftrio.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Biopharmaceutical companies focus on developing innovative therapies for various diseases.
Positioning
Vertex Pharmaceuticals Inc. is a dominant player in the CF market. Its competitive advantage lies in its portfolio of approved CFTR modulators. The company is also expanding into other therapeutic areas.
Total Addressable Market (TAM)
The overall pharmaceutical market is valued at over $1 trillion globally. Vertex's TAM within CF is substantial, and its expansion into new areas like pain, AATD and SCD increases its potential market reach. CF market is approximately $20 billion globally.
Upturn SWOT Analysis
Strengths
- Dominant position in the CF market
- Strong portfolio of CFTR modulators
- Robust R&D pipeline
- Strong financial performance
Weaknesses
- High dependence on the CF market
- Competition from potential gene therapies for CF
- Risk associated with clinical trial failures
- Reliance on a limited number of products
Opportunities
- Expansion into other therapeutic areas
- Acquisition of complementary technologies or companies
- Development of next-generation CF therapies
- Penetration into emerging markets
Threats
- Generic competition for older CF drugs
- Regulatory challenges
- Pricing pressures
- Competition from companies developing curative therapies for CF
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- REGN
Competitive Landscape
Vertex has a significant advantage in the CF market due to its approved therapies. Competition is increasing in other therapeutic areas.
Major Acquisitions
Alpine Therapeutics
- Year: 2024
- Acquisition Price (USD millions): 65
- Strategic Rationale: Acquisition of Alpine Therapeutics to expand expertise in inflammatory diseases.
Growth Trajectory and Initiatives
Historical Growth: Vertex has experienced significant growth in revenue and earnings over the past decade, primarily due to the success of its CF therapies.
Future Projections: Analysts project continued growth in revenue and earnings, driven by the expansion of Trikafta/Kaftrio and the development of new therapies. Revenue expected at 11.7B in 2024 and 13.2B in 2025. EPS expected at 15.77 in 2024 and 17.60 in 2025.
Recent Initiatives: Vertex has been actively pursuing acquisitions and collaborations to expand its pipeline and therapeutic focus. Acquisition of Alpine Therapeutics, collaboration with CRISPR Therapeutics.
Summary
Vertex Pharmaceuticals is a strong company, primarily due to its dominance in the cystic fibrosis market. Its robust pipeline and strong financial performance support its growth trajectory. However, its reliance on CF therapies and potential competition in that market require careful monitoring. Expansion into other therapeutic areas through acquisitions and collaborations is vital for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Analyst Reports
- Company Press Releases
- IBISWorld
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change over time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vertex Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-07-24 | CEO, President & Director Dr. Reshma Kewalramani FASN, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6100 | Website https://www.vrtx.com |
Full time employees 6100 | Website https://www.vrtx.com | ||
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.